logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line

< Back

Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line

Drugs

Cancer and Palliative Care

December 2017


Venetoclax is a drug that attaches to a protein in the body called Bcl-2. This protein presents in high amounts in CLL cancer cells, where it helps the cancer cells survive for longer in the body and makes them resistant to cancer medicines. Venetoclax causes the death of cancer cells and thereby slows the progression of the disease. In combination with obinutuzumab the body’s immune system gets strengthened. If licenced, venetoclax with obinutuzumab will offer an additional treatment option for patients with previously untreated CLL.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Venetoclax and Obinutuzumab for CLL



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts